BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

884 related articles for article (PubMed ID: 8938795)

  • 1. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
    Goldwasser F; Bae I; Fornace AJ; Pommier Y
    Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.
    Goldwasser F; Shimizu T; Jackman J; Hoki Y; O'Connor PM; Kohn KW; Pommier Y
    Cancer Res; 1996 Oct; 56(19):4430-7. PubMed ID: 8813137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.
    Gupta M; Fan S; Zhan Q; Kohn KW; O'Connor PM; Pommier Y
    Clin Cancer Res; 1997 Sep; 3(9):1653-60. PubMed ID: 9815856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors.
    Giuliano M; Lauricella M; Vassallo E; Carabillò M; Vento R; Tesoriere G
    Invest Ophthalmol Vis Sci; 1998 Jul; 39(8):1300-11. PubMed ID: 9660477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.
    Debernardis D; Siré EG; De Feudis P; Vikhanskaya F; Valenti M; Russo P; Parodi S; D'Incalci M; Broggini M
    Cancer Res; 1997 Mar; 57(5):870-4. PubMed ID: 9041188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death.
    Sané AT; Bertrand R
    Cancer Res; 1999 Aug; 59(15):3565-9. PubMed ID: 10446962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
    Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
    Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
    Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of BCL2 family member MCL1 as an early response to DNA damage.
    Zhan Q; Bieszczad CK; Bae I; Fornace AJ; Craig RW
    Oncogene; 1997 Mar; 14(9):1031-9. PubMed ID: 9070651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects.
    Zhou Y; Gwadry FG; Reinhold WC; Miller LD; Smith LH; Scherf U; Liu ET; Kohn KW; Pommier Y; Weinstein JN
    Cancer Res; 2002 Mar; 62(6):1688-95. PubMed ID: 11912141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells.
    Sun SY; Yue P; Wu GS; El-Deiry WS; Shroot B; Hong WK; Lotan R
    Oncogene; 1999 Apr; 18(14):2357-65. PubMed ID: 10327056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-alpha induced p21(WAF1) but not Bax in colon cancer cells WiDr with mutated p53: important role of protein stabilization.
    Kobayashi N; Takada Y; Hachiya M; Ando K; Nakajima N; Akashi M
    Cytokine; 2000 Dec; 12(12):1745-54. PubMed ID: 11097743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
    Hentze H; Latta M; Künstle G; Dhakshinamoorthy S; Ng PY; Porter AG; Wendel A
    Hepatology; 2004 May; 39(5):1311-20. PubMed ID: 15122760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-xL modulates apoptosis induced by anticancer drugs and delays DEVDase and DNA fragmentation-promoting activities.
    Schmitt E; Cimoli G; Steyaert A; Bertrand R
    Exp Cell Res; 1998 Apr; 240(1):107-21. PubMed ID: 9570926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.
    Bertrand R; Sarang M; Jenkin J; Kerrigan D; Pommier Y
    Cancer Res; 1991 Dec; 51(23 Pt 1):6280-5. PubMed ID: 1933888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells.
    Shao ZM; Dawson MI; Li XS; Rishi AK; Sheikh MS; Han QX; Ordonez JV; Shroot B; Fontana JA
    Oncogene; 1995 Aug; 11(3):493-504. PubMed ID: 7630633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells.
    Shao RG; Cao CX; Nieves-Neira W; Dimanche-Boitrel MT; Solary E; Pommier Y
    Oncogene; 2001 Apr; 20(15):1852-9. PubMed ID: 11313933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
    Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
    Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.